| Literature DB >> 29866093 |
Won-Il Choi1, Sonila Dauti2,3, Hyun Jung Kim2, Sun Hyo Park2, Jae Seok Park2, Choong Won Lee4.
Abstract
BACKGROUND: Understanding the risk factors that are associated with the development of interstitial lung disease might have an important role in understanding the pathogenetic mechanism of interstitial lung disease as well as prevention. We aimed to determine independent risk factors of interstitial lung disease development.Entities:
Keywords: Epidemiology; Interstitial lung disease; Risk factor
Mesh:
Year: 2018 PMID: 29866093 PMCID: PMC5987651 DOI: 10.1186/s12890-018-0660-2
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Flow chart of the study for selection of patients with interstitial lung disease (ILD). ICD: International Classification of Disease
Baseline characteristics of patients with interstitial lung disease (n = 1972) and controls (n = 310,547)
| Variable | Interstitial lung disease No. (%) | Control No. (%) | |||
|---|---|---|---|---|---|
| Sex | |||||
| Male | 1265 | (64.1) | 151,124 | (48.7) | < 0.001 |
| Female | 707 | (35.9) | 159,423 | (51.3) | |
| Age group (years) | |||||
| 40–49 | 354 | (18.0) | 136,576 | (44.0) | < 0.001 |
| 50–59 | 474 | (24.0) | 89,952 | (29.0) | |
| 60–69 | 662 | (33.6) | 57,189 | (18.4) | |
| ≥ 70 | 482 | (24.4) | 26,830 | (8.6) | |
| Baseline comorbidity | |||||
| Malignancy | 357 | (18.1) | 43,007 | (13.8) | < 0.001 |
| Diabetes | 479 | (24.3) | 48,507 | (15.6) | < 0.001 |
| Chronic renal failure | 27 | (1.4) | 2187 | (0.7) | < 0.001 |
| COPDa | 242 | (12.3) | 11,204 | (3.6) | < 0.001 |
| Past history | |||||
| Herpes (B00, B02) | 65 | (3.3) | 9997 | (3.2) | 0.85 |
| Tuberculosis (A15, A16, B90) | 102 | (5.2) | 5467 | (1.8) | < 0.001 |
| Pneumonia (J12-J18) | 98 | (5.0) | 6709 | (2.2) | < 0.001 |
| Hepatitis C (B18.2) | 28 | (1.4) | 2068 | (0.7) | < 0.001 |
| Hepatitis B (B18.0, B18.1) | 66 | (3.3) | 9859 | (3.2) | 0.66 |
| GERDb (K21) | 227 | (11.5) | 26,643 | (8.6) | < 0.001 |
| Smoker (ex-smoker or current smoker) | 748 | (37.9) | 93,573 | (30.1) | < 0.001 |
| Household income (Quartiles), % | |||||
| 81–100 | 870 | (44.1) | 131,363 | (42.3) | 0.11 |
| 41–80 | 635 | (32.2) | 107,310 | (34.6) | |
| 11–40 | 437 | (22.2) | 66,372 | (21.4) | |
| 0–10 | 30 | (1.5) | 5502 | (1.8) | |
aCOPD chronic obstructive pulmonary disease, b GERD gastroesophageal reflux disorder
Univariate and multivariate Cox regression analyses for development of interstitial lung disease during the 9-year follow-up period
| Risk factor | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Men (reference: women) | 1.9 (1.7–2.1) | < 0.001 | 1.9 (1.7–2.1) | < 0.001 |
| Age group (years) (reference: 40–49) | ||||
| 50–59 | 1.9 (1.7–2.2) | < 0.001 | 1.9 (1.7–2.2) | < 0.001 |
| 60–69 | 4.3 (3.8–4.9) | < 0.001 | 4.1 (3.6–4.7) | < 0.001 |
| ≥70 | 7.1 (6.2–8.2) | < 0.001 | 6.9 (5.9–8.0) | < 0.001 |
| Diabetes (reference: no) | 1.6 (1.5–1.8) | < 0.001 | 1.1 (0.9–1.2) | 0.06 |
| COPD (reference: no) | 3.7 (3.2–4.2) | < 0.001 | 1.8 (1.6–2.1) | < 0.001 |
| GERD (reference: no) | 1.3 (1.1–1.5) | < 0.001 | 1.0 (0.9–1.3) | 0.31 |
| History of herpes (reference: no) | 0.97 (0.7–1.2) | 0.85 | 0.9 (0.7–1.2) | 0.92 |
| History of tuberculosis (reference: no) | 3.0 (2.4–3.7) | < 0.001 | 1.5 (1.1–1.9) | 0.003 |
| History of pneumonia (reference: no) | 2.2 (1.8–2.7) | < 0.001 | 1.6 (1.3–2.0) | < 0.001 |
| Hepatitis C (reference: no) | 2.1 (1.4–3.0) | < 0.001 | 1.6 (1.1–2.3) | 0.01 |
| Hepatitis B (reference: no) | 1.0 (0.8–1.3) | 0.84 | 0.8 (0.7–1.1) | 0.39 |
| Smoker (reference: never smoker) | 1.4 (1.3–1.6) | < 0.001 | 1.2 (1.1–1.4) | < 0.001 |
| Household income, % (reference: 81–100 | ||||
| 41–80 | 0.8 (0.8–0.9) | 0.04 | 0.9 (0.8–1.0) | 0.35 |
| 11–40 | 1.0 (0.9–1.1) | 0.85 | 0.9 (0.8–1.1) | 0.87 |
| 0–10 | 1.1 (0.8–1.6) | 0.39 | 1.1 (0.7–1.5) | 0.59 |
HR hazard ratio, CI confidence interval, COPD chronic obstructive pulmonary disease, GERD gastroesophageal reflux disorder
Multivariate Cox regression analyses with forward stepwise variable selection method for development of interstitial lung disease during the 9-year follow-up period
| Risk factor | Males | Females | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Age group (years) (reference: 40–49) | ||||
| 50–59 | 2.3 (1.9–2.7) | < 0.001 | 1.4 (1.1–1.7) | 0.004 |
| 60–69 | 4.6 (3.9–5.5) | < 0.001 | 3.3 (2.6–4.1) | < 0.001 |
| ≥70 | 8.1 (6.7–9.7) | < 0.001 | 5.4 (4.3–6.7) | < 0.001 |
| Malignancy | 1.1 (1.0–1.3) | 0.045 | 1.0 (0.8–1.2) | 0.68 |
| Diabetes (reference: no) | 1.2 (1.0–1.3) | 0.006 | 0.9 (0.7–1.1) | 0.38 |
| COPD (reference: no) | 1.8 (1.5–2.2) | < 0.001 | 1.9 (1.5–2.4) | < 0.001 |
| History of tuberculosis (reference: no) | 1.5 (1.2–2.0) | < 0.001 | 1.8 (1.2–2.6) | 0.001 |
| History of pneumonia (reference: no) | 1.5 (1.1–2.0) | 0.002 | 1.7 (1.2–2.3) | 0.001 |
| Hepatitis C (reference: no) | 1.3 (0.8–2.1) | 0.26 | 2.1 (1.1–3.8) | 0.014 |
| GERD (reference: no) | 1.0 (0.9–1.3) | 0.38 | 1.3 (1.0–1.6) | 0.013 |
| Smoker (reference: never smoker) | 1.2 (1.1–1.4) | < 0.001 | 1.5 (1.1–2.0) | 0.005 |
HR hazard ratio, CI confidence interval, COPD chronic obstructive pulmonary disease, GERD gastroesophageal reflux disorder